AZD1981 is primarily investigated for its potential therapeutic applications in the treatment of chronic obstructive pulmonary disease (COPD) and asthma. It functions as a selective antagonist of the CRTh2 receptor, which plays a key role in the inflammatory pathways associated with these respiratory conditions. By blocking this receptor, AZD1981 aims to reduce inflammation, improve lung function, and alleviate symptoms such as breathlessness and wheezing. Its development is focused on providing a targeted approach to manage chronic inflammatory diseases of the airways, offering a potential alternative to traditional treatments like corticosteroids. Research continues to explore its efficacy and safety in clinical settings.